Search company, investor...

Biolex Therapeutics

Founded Year

1997

Stage

Dead | Dead

Total Raised

$217.22M

About Biolex Therapeutics

Biolex Therapeutics is a clinical-stage biopharmaceutical company that uses the LEX System to develop follow-on biologics, hard-to-make therapeutic proteins and monoclonal antibodies that have been optimized to enhance efficacy and potency. The LEX System genetically transforms the aquatic plant Lemna to enable the production of biologic product candidates.

Headquarters Location

158 Credle Street

Pittsboro, North Carolina, 27312,

United States

919-542-9901

Missing: Biolex Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Biolex Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Biolex Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Biolex Therapeutics is included in 1 Expert Collection, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Biolex Therapeutics Patents

Biolex Therapeutics has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/30/2009

3/12/2013

Influenza, Virology, Vaccines, Animal virology, Epidemiology

Grant

Application Date

11/30/2009

Grant Date

3/12/2013

Title

Related Topics

Influenza, Virology, Vaccines, Animal virology, Epidemiology

Status

Grant

Latest Biolex Therapeutics News

Biolex Therapeutics Inc. Mergers Acquisitions MA Partnerships Alliances and Investment Report Prices from USD $350

Nov 29, 2016

Biolex Therapeutics, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 06:20 EST 29 Nov 2016 | BioPortfolio Reports Home » Topics » Biotechnology Business » Latest News » Biolex Therapeutics, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 Summary MarketLine's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Biolex Therapeutics, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Biolex Therapeutics, Inc. since January 2007. Key Findings Provides intelligence on Biolex Therapeutics, Inc.'s MA, strategic partnerships and alliances, capital raising and private equity transactions. Detailed reports of various financial transactions undertaken by Biolex Therapeutics, Inc. and its subsidiaries since 2007. Information about key financial and legal advisors for Biolex Therapeutics, Inc.'s financial deals transactions. Financial deals tables and charts covering deal value and volumes trend, deal types and geographybased deal activity. ReasonsToBuy Access comprehensive financial deals data along with charts and graph covering MA, private equity, and partnerships and alliances. Form an independent opinion about Biolex Therapeutics, Inc.'s growth strategies through the organic and inorganic activities undertaken since 2007. Track your competitors' business structure and growth strategies. Related Biotechnology, Pharmaceutical and Healthcare News

Biolex Therapeutics Frequently Asked Questions (FAQ)

  • When was Biolex Therapeutics founded?

    Biolex Therapeutics was founded in 1997.

  • Where is Biolex Therapeutics's headquarters?

    Biolex Therapeutics's headquarters is located at 158 Credle Street, Pittsboro.

  • What is Biolex Therapeutics's latest funding round?

    Biolex Therapeutics's latest funding round is Dead.

  • How much did Biolex Therapeutics raise?

    Biolex Therapeutics raised a total of $217.22M.

  • Who are the investors of Biolex Therapeutics?

    Investors of Biolex Therapeutics include Quaker BioVentures, InterSouth Partners, Investor Growth Capital, Clarus, Polaris Partners and 22 more.

  • Who are Biolex Therapeutics's competitors?

    Competitors of Biolex Therapeutics include Five Prime Therapeutics, 2cureX, Actimis Pharmaceuticals, BrightPath Biotherapeutics, CeNeRx BioPharma and 12 more.

Compare Biolex Therapeutics to Competitors

A
Actimis Pharmaceuticals

Actimis Pharmaceuticals is a bio-pharmaceutical company focused on the development of small molecule therapeutics for respiratory and inflammatory disorders.

G
Graffinity Pharmaceuticals AG

Graffinity is a partner for fragment based drug discovery and lead development of small molecule pharmaceuticals

ABMART Logo
ABMART

Abmart aims to develop highly scaled production of antibodies for the drug discovery applications

C
Combichem

Combichem offers drug discovery and development services

T
TcLand

TcLand Expression is a provider in the field of gene expression biomarkers in immunology

M
Molecular LogiX

Molecular LogiX (MLX) is a drug discovery company located in The Woodlands, Texas, that seeks to discover therapeutics through the application of rationale protein engineering technologies. The company is currently developing protein-based drugs to treat cancer by interfering with established tumor growth factor pathways.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.